J&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
Janssen Biotech, one of the pharmaceutical subsidiaries of Johnson & Johnson, has entered a worldwide licensing agreement with Protagonist Therapeutics for rights to its experimental inflammatory bowel disease candidate PTG-200.